公开(公告)号：US20230190883A1

公开(公告)日：2023-06-22

申请号：US17928381

申请日：2021-05-28

Applicant: Bessor Pharma, LLC

Inventor： Gary Desir ,  Arthur Felix ,  Wallace Dairman ,  Anthony Barrett ,  Barry Berkowitz

IPC: A61K38/44 ,  C12N9/02 ,  A61P13/12 ,  A61P1/18

CPC classification number: A61K38/44 ,  C12N9/0036 ,  C12Y106/03 ,  A61P13/12 ,  A61P1/18

Abstract: Disclosed are stable peptides that have renalase agonist activity and are useful for treating diseases such as AKI and AP, including those relating to SARS-CoV-2

公开(公告)号：US20230181628A1

公开(公告)日：2023-06-15

申请号：US17999347

申请日：2021-05-19

Applicant: OSAKA UNIVERSITY

Inventor： Kazutake TSUJIKAWA ,  Kiyoto TAKAMORI ,  Takekatsu SHIBATA

IPC: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

CPC classification number: A61K33/14 ,  A61P35/00 ,  A61P13/10 ,  A61K31/14 ,  A61P15/00 ,  A61P1/00 ,  A61P1/18

Abstract: The present invention provides an epithelial cancer therapeutic agent with less side effects. In order to achieve the above object, an epithelial cancer therapeutic agent of the present invention includes: at least one material selected from the group consisting of oxo acid, oxo acid ion, and oxo acid salt, wherein the epithelial cancer therapeutic agent treats or prevents epithelial cancer.

公开(公告)号：US20230158015A1

公开(公告)日：2023-05-25

申请号：US17802956

申请日：2021-03-03

Applicant: Gina E. VOTTA-VELLIS ,  SINTETICA S.A.

Inventor： AUGUSTO MITIDIERI ,  ELISABETTA DONATI ,  ALAIN BORGEAT ,  E. GINA VOTTA-VELIS ,  MIRO VENTURI

IPC: A61K31/485 ,  A61K31/167 ,  A61K9/00 ,  A61P41/00 ,  A61P35/00 ,  A61P25/04 ,  A61P29/00 ,  A61P35/04 ,  A61P1/18

CPC classification number: A61K31/485 ,  A61K9/0019 ,  A61K31/167 ,  A61P1/18 ,  A61P25/04 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P41/00

Abstract: Combinations of compounds that inhibit activation of p-Src tyrosine kinase, having particularly utility in the treatment of inflammation resulting from traumatic surgical interventions and the proliferation or metastasis of cancer cells following surgical excision of cancerous tissue.

公开(公告)号：US20230149399A1

公开(公告)日：2023-05-18

申请号：US18093599

申请日：2023-01-05

Applicant: Usher III Initiative, Inc.

Inventor： Mahdi FARHAN ,  James M. HAMBY ,  Tracey L. FLETCHER

IPC: A61K31/5025 ,  A61K45/06 ,  A61P35/00 ,  A61P15/08 ,  A61P17/00 ,  A61P1/18 ,  A61P1/00 ,  A61P13/08 ,  A61P19/08 ,  A61P25/00

CPC classification number: A61K31/5025 ,  A61K45/06 ,  A61P35/00 ,  A61P15/08 ,  A61P17/00 ,  A61P1/18 ,  A61P1/00 ,  A61P13/08 ,  A61P19/08 ,  A61P25/00

Abstract: The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

公开(公告)号：US20190231753A1

公开(公告)日：2019-08-01

申请号：US16332913

申请日：2017-09-13

Applicant: Marco CIPOLLI

Inventor： Marco CIPOLLI ,  Valentino BEZZERRI ,  Baroukh Maurice ASSAEL

IPC: A61K31/4245 ,  A61P1/18 ,  A61P7/06 ,  A61P43/00

CPC classification number: A61K31/4245 ,  A61P1/18 ,  A61P7/06 ,  A61P43/00

Abstract: The invention relates to compounds for the treatment of ribosomopathies. In particular, it refers to compounds for the treatment of Shwachman-Diamond Syndrome (SDS) and other ribosomopathies, such as Diamond-Blackfan Anemia (DBA), X-linked dyskeratosiscongenita (DKC) and Treacher Collins syndrome (TCS).

公开(公告)号：US20190201490A1

公开(公告)日：2019-07-04

申请号：US16304080

申请日：2017-05-24

Applicant: Board of Regents, The University of Texas System

Inventor： David J. Mangelsdorf ,  Steven A. KLIEWER ,  Katie C. COATE ,  Genaro HERNANDEZ

IPC: A61K38/18 ,  A61P1/18 ,  A61K9/00

CPC classification number: A61K38/1825 ,  A61K9/0019 ,  A61K9/0053 ,  A61P1/18 ,  C07K14/50

Abstract: The present invention relates to the treatment of secretory disorders, and provides novel methods of treatment of these disorders comprising the administration of fibroblast growth factor 21 (FGF21) or derivatives thereof. The methods of the invention are useful in conditions including exocrine pancreatic insufficiency (EPI), for example EPI resulting from cystic fibrosis, alcoholism, pancreatitis, pancreatic cancer, gallstones, celiac disease, high triglycerides, or lupus. The methods of the present invention find further utility in the treatment of salivary flow disorders, for example Sjorgen's syndrome, and the prevention of EPI or pancreatitis resulting from surgical procedures.

公开(公告)号：US20190023657A1

公开(公告)日：2019-01-24

申请号：US16138369

申请日：2018-09-21

Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.

Inventor： Fumihiko SAITOH ,  Hiroshi NAGASUE

IPC: C07D213/75 ,  A61K45/06 ,  A61K31/4418 ,  C07D401/04 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/84 ,  C07D405/04 ,  A61K31/4433 ,  C07D405/14 ,  C07D213/81 ,  C07D413/12 ,  C07D417/04

CPC classification number: C07D213/75 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61K45/06 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/14 ,  A61P7/00 ,  A61P9/00 ,  A61P9/06 ,  A61P9/12 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P11/06 ,  A61P13/02 ,  A61P13/08 ,  A61P13/10 ,  A61P13/12 ,  A61P15/00 ,  A61P17/00 ,  A61P19/02 ,  A61P19/10 ,  A61P21/00 ,  A61P21/02 ,  A61P25/00 ,  A61P25/04 ,  A61P25/08 ,  A61P25/16 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P29/02 ,  A61P31/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07B2200/07 ,  C07C215/44 ,  C07C271/24 ,  C07C2602/10 ,  C07D213/81 ,  C07D213/84 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D413/12 ,  C07D417/04

Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

公开(公告)号：US20180353507A1

公开(公告)日：2018-12-13

申请号：US15780462

申请日：2016-12-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： David E. Kelley ,  Ping Liu ,  Harold B. Wood ,  Scott D. Edmondson ,  Hideo Makimura ,  Xiaoyan Li ,  Timothy Joseph Kowalski

IPC: A61K31/506 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  A61P1/18

CPC classification number: A61K31/506 ,  A61K31/00 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  A61P1/18 ,  C12Q1/02 ,  G01N33/74 ,  G01N2333/726 ,  G01N2800/042

Abstract: Use of a GPR119 agonist in the prevention or treatment of hypoglycemia is disclosed, addition, pharmaceutical compositions and combinations of a GPR1 19 agonist with insulin, insulin analog, insulin secretagogue or or other drug(s) that reduces plasma glucose levels to below 70 mg/dL described herein.

公开(公告)号：US20180325840A1

公开(公告)日：2018-11-15

申请号：US15777385

申请日：2016-11-21

Applicant: NATIONAL DEFENSE EDUCATION AND RESEARCH FOUNDATION

Inventor： Oliver Yoa-Pu HU ,  Hsin-Tien HO ,  Yung-En WU ,  Hsi-Hui TANG

IPC: A61K31/045 ,  A61K31/047 ,  A61K31/353 ,  A61K31/428 ,  A61P1/18 ,  A23L33/10

CPC classification number: A61K31/045 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/047 ,  A61K31/353 ,  A61K31/428 ,  A61K31/7048 ,  A61P1/18

Abstract: The present invention relates to a composition and method for preventing or treating fatty pancreas, or ameliorating a pancreas disease caused by fatty pancreas, diabetes mellitus or other related disorders.

公开(公告)号：US20180319894A1

公开(公告)日：2018-11-08

申请号：US15773450

申请日：2016-11-02

Applicant: Mayo Foundation for Medical Education and Research

Inventor： Vijay P. Singh

IPC: C07K16/40 ,  A61K31/365 ,  A61P1/18

CPC classification number: C07K16/40 ,  A61K31/337 ,  A61K31/365 ,  A61K31/536 ,  A61K2039/505 ,  A61P1/18 ,  C07K16/18 ,  C07K2317/76

Abstract: This document provides materials and methods for treating pancreatitis (e.g., severe acute pancreatitis), a complication associated with pancreatitis (e.g., organ failure), and/or an acute inflammatory condition in a mammal (e.g., inflammation from a burn or trauma). For example, methods and materials for using one or more colipase inhibitors to treat a mammal having pancreatitis (e.g., acute pancreatitis) are provided.